Results 41 to 50 of about 2,008,123 (283)

GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. [PDF]

, 2016
Abnormal activation of the epidermal growth factor receptor (EGFR) due to a deletion of exons 2-7 of EGFR (EGFRvIII) is a common alteration in glioblastoma (GBM). While this alteration can drive gliomagenesis, tumors harboring EGFRvIII are heterogeneous.
David James, C, Engler, Jane R, Ewald, Andrew J, Gong, Henry, Huillard, Emmanuelle, Koshkakaryan, Gayane, Lindberg, Olle R, McKinney, Andrew, Molinaro, Annette M, Phillips, Joanna J, Robinson, Aaron E, Shieh, Joseph T   +11 more
core   +1 more source

Selective Desensitization of Growth Factor Signaling by Cell Adhesion to Fibronectin [PDF]

, 2007
Cell adhesion to the extracellular matrix is required to execute growth factor (GF)-mediated cell behaviors, such as proliferation. A major underlying mechanism is that cell adhesion enhances GF-mediated intracellular signals, such as extracellular ...
Asthagiri, Anand R., Galownia, Niki C., Gong, Yuan, Kushiro, Keiichiro   +3 more
core   +1 more source

Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Technology in Cancer Research & Treatment, 2020
Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM, Yi Hou PhD, Liang-Chen Qi MD   +2 more
doaj   +1 more source

Triple negative breast cancer: new perspectives for targeted therapies [PDF]

, 2015
Breast cancer is a heterogeneous disease, encompassing a large number of entities showing different morphological features and having clinical behaviors.
Caruso, Davide, Frati, Luigi, Minozzi, Marina, Papa, Anselmo, Rossi, Luigi, Tomao, Federica, Tomao, Silverio, Vici, Patrizia, Zaccarelli, Eleonora   +8 more
core   +1 more source

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients

Clinics, 2012
OBJECTIVE: Epidermal growth factor receptor is involved in the pathogenesis of non-small cell lung cancer and has recently emerged as an important target for molecular therapeutics.
Carlos E. Bacchi, Heloísa Ciol, Eduardo M. Queiroga, Lucimara C. Benine, Luciana H. Silva, Elida B. Ojopi   +5 more
doaj   +1 more source

miRNA-9 Inhibits Proliferation and Migration of Lung Squamous Cell Carcinoma Cells by Regulating NRSF/EGFR

Technology in Cancer Research & Treatment, 2020
Background: To investigate the mechanism of microRNA9 in inhibiting proliferation and migration of lung squamous cell carcinoma cells via neuron-restricted silencing factor/epidermal growth factor receptor.
Kangning Wang MD, Kai Xu MM, Xuefeng Leng MD, Yongtao Han BM, Qiang Fang MD   +4 more
doaj   +1 more source

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report [PDF]

, 2013
BACKGROUND: Although a number of studies have reported acquired drug resistance due to administration of epidermal growth factor receptor antibody inhibitors, the underlying causes of this phenomenon remain unclear.
Akio Saiura, Eiji Shinozaki, Hiroki Osumi, Masashi Ueno, Mitsukuni Suenaga, Mun Mingyon, Nobuyuki Mizunuma, Satoshi Matsusaka, Toshiharu Yamaguchi   +8 more
core   +1 more source

Epidermal growth factor receptor in glioblastoma

Oncology Letters, 2017
Mutations in the epidermal growth factor receptor (EGFR) are commonly occurring in glioblastoma. Enhanced activation of EGFR can occur through a variety of different mechanisms, both ligand-dependent and ligand-independent.
Hongsheng Xu, Hailiang Zong, Chong Ma, Xing Ming, M. Shang, Kai Li, Xiaoguang He, Hai Du, Lei Cao   +8 more
semanticscholar   +1 more source

Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]

, 2008
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad, Daley, George, Gray, Nathanael, KURIYAN, John, Seeliger, Markus   +4 more
core   +1 more source

Control of human endometrial stromal cell motility by PDGF-BB, HB-EGF and trophoblast-secreted factors [PDF]

, 2013
Human implantation involves extensive tissue remodeling at the fetal-maternal interface. It is becoming increasingly evident that not only trophoblast, but also decidualizing endometrial stromal cells are inherently motile and invasive, and likely ...
A Brar, A Samalecos, A Stavreus-Evers, AA Brahmbhatt, Ana-Maria Bamberger, Anja Wolf, Annemarie Samalecos, AT Fazleabas, B Cloke, B Gellersen, B Gellersen, BA Lessey, Birgit Gellersen, C Ferretti, C Fischer, C Gaggioli, Charlotte H. E. Weimar, CHE Weimar, CM Boomsma, CP Thomas, D Gentilini, D Gentilini, D Haouzi, DE Clark, EE Sander, ER Norwitz, F Chang, F Llorens, F Lyall, G Gaus, G Teklenburg, G Teklenburg, GE Lash, GE Lash, GJ Burton, H Funayama, H Matsumoto, H Xie, HJ Lim, HJ Yoo, I Ihnatovych, IY Yotova, J Anacker, J Baulida, J Fiedler, JJ Brosens, JJ Brosens, JW Tullai, JX Zhu, K Chobotova, K Kawada, K Red-Horse, K Roepstorff, LA Salamonsen, M Bilban, M Bilban, M Cohen, M Gonzalez, M Knöfler, M Knöfler, M Salker, Maren Schwenke, Martin Knöfler, Meijing Wang, Michelle Kruse, MW Maijenburg, Nick S. Macklon, NJ Hannan, NJ Hannan, P Burke, P Jessmon, P Jessmon, P Kaufmann, Philipp Velicky, R Apps, RE Leach, RE Leach, RE Leach, RJ Petrie, RL Kendall, RN Popovici, S Grewal, S Grewal, SK Mitra, Y Jiang, Y Yamazaki   +85 more
core   +7 more sources